Filing Details

Accession Number:
0001104659-23-073872
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-06-22 18:23:24
Reporting Period:
2023-06-20
Accepted Time:
2023-06-22 18:23:24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1829635 Transcode Therapeutics Inc. RNAZ Pharmaceutical Preparations (2834) 811065054
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1854161 Michael Robert Dudley C/O Transcode Therapeutics, Inc.
6 Liberty Square, #2382
Boston MA 02109
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-06-20 6,607 $2.55 70,262 No 4 P Direct
Common Stock Acquisiton 2023-06-21 12,000 $2.65 82,262 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Footnotes
  1. Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.54 to $2.55. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.
  2. Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.60 to $2.70. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.